What are Amyloid Plaques?

Amyloid plaques are aggregates of misfolded proteins that form in the spaces between nerve cells. These abnormally configured proteins are thought to play a central role in Alzheimer's disease. The amyloid plaques first develop in the areas of the brain concerned with memory and other cognitive functions.

The amyloid hypothesis

Amyloid plaques form when pieces of protein called beta-amyloid aggregate. The beta-amyloid is produced when a much larger protein referred to as the amyloid precurosr protein (APP) is broken down. APP is composed of 771 amino acids and is cleaved by two enzymes to produce beta-amyloid. The large protein is first cut by beta secretase and then by gamma secretase, producing beta-amyloid pieces that may be made up of 38, 40 or 42 amino acids. The beta-amyloid composed of 42 amino acids is chemically “stickier” than the other lengths and therefore is more likely to form plaques. Research has shown that three genetic abnormalities that are associated with early stage Alzheimer’s disease each change the function of gamma secretase in a way that leads to an increased production of beta-amyloid 42.

How beta-amyloid causes toxic damage to nerve cells is not quite clear, but some research suggests that it may split into fragments and release free radicals, which then attack neurons. Another theory is that the beta-amyloid forms tiny holes in neuronal membranes, which leads to an unregulated influx of calcium that can cause neuronal death. Regardless of the exact pathological process through which beta-amyloid causes neuronal damage, the result is that neurons die.

Plaques then form that are made up of a mixture of these degenerating neurons and the beta-amyloid aggregates. These plaques cannot be broken down and removed by the body, so they gradually accumulate in the brain. The accumulation of this amyloid leads to amyloidosis, which is thought to contribute to a number of neurodegenerative diseases.

Amyloid plaques form one of the two defining features of Alzheimer’s disease, the other being neurofibrillary tangles. Beta-amyloid is also thought to be responsible for the formation of these tangles, which again damage neurons and cause the symptoms of dementia. Technically, a person may present with all of the characteristics of Alzheimer’s disease but if a brain biopsy or positron emission tomography does not reveal the presence of amyloid plaques or neurofibrillary tangles, a diagnosis of Alzheimer’s disease will not be made.


The treatment currently available to treat Alzheimer’s disease only addresses symptoms rather than the underlying cause, but research that focuses on the amyloid hypothesis and  improves understanding of this protein’s role in the disease is hoped to lead to the development of new treatments that may be able to delay or stop disease progression.

Several treatments that either remove beta-amyloid or interfere with its production from APP are currently being designed and tested. Approaches to preventing beta-amyloid production involve targeting the beta-secretase and gamma-secretase that are required to make it from APP. Some research in animal models has shown preventing the action of these two enzymes to be successful and several drugs based on this mechanism have reached Phase III trails.  Another approach that has been investigated is preventing the aggregation of beta-amyloid in order to prevent plaque formation. Several drug candidates have been identified that seem to prevent this protein clumping and these agents are now due to be tested in animal models of Alzheimer’s disease.

Another approach currently being investigated is the removal of the amyloid plaques or proteins that form in the brain. In 2014, researchers from Stanford University published the ground breaking results of a study that investigated the function of microglia in amyloid plaque formation. Microglia are resident macrophages in the central nervous system that are responsible for removing bacteria, viruses and abnormal deposits from the brain in order to maintain its function. The researchers found that nerve cells die when the microglia stop working (which tends to occur as people age) and a protein referred to as EP2 stops the microglia from functioning efficiently. By blocking this protein, the team found the normal function of microglia was restored, which allowed them to clean up the sticky amyloid plaques which accumulate in Alzheimer’s disease. When a drug was used to block EP2 in mice, the researchers found that memory loss was reversed in the animals as well as many other symptoms of the disease.

Overall, laboratory research has shown promising evidence that it may be possible to prevent the formation of amyloid plaques or to boost the brain’s immune response to  clear the deposits once they have formed. Results from trials in humans over the next five years should indicate whether a cure for Alzheimer’s disease is indeed a realistic possibility in the future.

Last Updated: Jan 2, 2023

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2023, January 02). What are Amyloid Plaques?. News-Medical. Retrieved on June 19, 2024 from https://www.news-medical.net/health/What-are-Amyloid-Plaques.aspx.

  • MLA

    Robertson, Sally. "What are Amyloid Plaques?". News-Medical. 19 June 2024. <https://www.news-medical.net/health/What-are-Amyloid-Plaques.aspx>.

  • Chicago

    Robertson, Sally. "What are Amyloid Plaques?". News-Medical. https://www.news-medical.net/health/What-are-Amyloid-Plaques.aspx. (accessed June 19, 2024).

  • Harvard

    Robertson, Sally. 2023. What are Amyloid Plaques?. News-Medical, viewed 19 June 2024, https://www.news-medical.net/health/What-are-Amyloid-Plaques.aspx.


  1. Tim Dunbar Tim Dunbar Canada says:

    Antabuse cleared out my cobwebs last August 2017. Two weeks later and felt so much better. The groggy, unbalanced feeling in my brain disappeared. (this was a medication I had on hand but could not use at the time as it would be in conflict with other meds I was on)
    I didn't use this to quit alcohol but a medical paper I was reading before hand suggested it could dissolve plaques and tangles! So I tried and life was good.

    I am now trying CBD cannibidoil, 15mg for a closer to natural substance and have noticed a similar effect.

    Are there other dissolvers we should know about?

  2. Jenny Wright Jenny Wright United Kingdom says:

    Does this cause vascular dementia?

  3. Imagen Gowan Imagen Gowan United Kingdom says:

    Here's hoping that a cure for this terrible disease is indeed possible in the near future.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances in understanding and detecting Alzheimer's disease